PL2533761T3 - Sposoby i kompozycje do wytwarzania aerozoli - Google Patents

Sposoby i kompozycje do wytwarzania aerozoli

Info

Publication number
PL2533761T3
PL2533761T3 PL11705486T PL11705486T PL2533761T3 PL 2533761 T3 PL2533761 T3 PL 2533761T3 PL 11705486 T PL11705486 T PL 11705486T PL 11705486 T PL11705486 T PL 11705486T PL 2533761 T3 PL2533761 T3 PL 2533761T3
Authority
PL
Poland
Prior art keywords
compositions
methods
producing aerosols
aerosols
producing
Prior art date
Application number
PL11705486T
Other languages
English (en)
Inventor
Erik Depla
Mauro Sergi
Peter Casteels
Original Assignee
Ablynx N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx N.V. filed Critical Ablynx N.V.
Publication of PL2533761T3 publication Critical patent/PL2533761T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11705486T 2010-02-11 2011-02-11 Sposoby i kompozycje do wytwarzania aerozoli PL2533761T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30344710P 2010-02-11 2010-02-11
US201061426610P 2010-12-23 2010-12-23
PCT/EP2011/052024 WO2011098552A2 (en) 2010-02-11 2011-02-11 Methods and compositions for the preparation of aerosols
EP11705486.6A EP2533761B1 (en) 2010-02-11 2011-02-11 Methods and compositions for the preparation of aerosols

Publications (1)

Publication Number Publication Date
PL2533761T3 true PL2533761T3 (pl) 2019-09-30

Family

ID=43899571

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19152522.9T PL3501499T3 (pl) 2010-02-11 2011-02-11 Sposoby i kompozycje do wytwarzania aerozoli
PL11705486T PL2533761T3 (pl) 2010-02-11 2011-02-11 Sposoby i kompozycje do wytwarzania aerozoli

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19152522.9T PL3501499T3 (pl) 2010-02-11 2011-02-11 Sposoby i kompozycje do wytwarzania aerozoli

Country Status (17)

Country Link
US (3) US9713589B2 (pl)
EP (2) EP3501499B1 (pl)
JP (3) JP5951508B2 (pl)
CN (2) CN105380904A (pl)
AU (1) AU2011214299B2 (pl)
CA (1) CA2787718C (pl)
CY (1) CY1122634T1 (pl)
DK (1) DK2533761T3 (pl)
ES (2) ES2738114T3 (pl)
HK (1) HK1222128A1 (pl)
HR (1) HRP20191071T1 (pl)
HU (1) HUE044292T2 (pl)
LT (1) LT2533761T (pl)
PL (2) PL3501499T3 (pl)
PT (2) PT3501499T (pl)
SI (1) SI2533761T1 (pl)
WO (1) WO2011098552A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004707C (en) 2009-09-02 2022-05-31 Synedgen Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
US9713589B2 (en) 2010-02-11 2017-07-25 Ablynx N.V. Methods and compositions for the preparation of aerosols
DK2544663T3 (en) 2010-03-12 2018-04-16 Berg Llc INTRAVENOUS FORMULATIONS OF COENZYM Q10 (CoQ10) AND PROCEDURES FOR USING IT
JP5932993B2 (ja) * 2011-06-17 2016-06-08 バーグ エルエルシー 吸入可能な医薬組成物
WO2014045213A1 (en) * 2012-09-18 2014-03-27 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
ES2993671T3 (en) 2013-03-15 2025-01-03 Univ Texas Peptide fttftvt for use in treating fibrosis
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
KR102337927B1 (ko) * 2014-04-03 2021-12-14 체에스엘 베링 아게 면역글로불린의 분무
JP2017526714A (ja) * 2014-09-11 2017-09-14 シネジェン， インコーポレイテッド 組成物およびその使用方法
HUE044199T2 (hu) 2014-10-10 2019-10-28 Ablynx Nv Inhalációs készülék légúti betegségek aeroszolos terápiájában való alkalmazásra
JP2017538779A (ja) * 2014-10-10 2017-12-28 アブリンクス・エヌ・フェー Ｒｓｖ感染の治療方法
CN107405379A (zh) * 2015-02-27 2017-11-28 得克萨斯州大学系统董事会 多肽治疗剂和其用途
US20190127447A1 (en) 2016-05-02 2019-05-02 Ablynx N.V. Treatment of rsv infection
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
KR20250011229A (ko) 2017-06-02 2025-01-21 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
WO2020055812A1 (en) 2018-09-10 2020-03-19 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
EP4096625A1 (en) * 2020-01-31 2022-12-07 Sanofi Biotechnology Pulmonary delivery of antibodies
EP4142740A4 (en) 2020-04-30 2024-01-24 Synedgen, Inc. Compositions and methods of use thereof
JP7476787B2 (ja) * 2020-12-23 2024-05-01 オムロンヘルスケア株式会社 管理装置、治療用吸入器、及び管理プログラム
WO2025186423A1 (en) 2024-03-07 2025-09-12 Csl Behring Ag Immunoglobulin composition and method of generating an aerosol

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US6014970A (en) 1998-06-11 2000-01-18 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US5586550A (en) 1995-08-31 1996-12-24 Fluid Propulsion Technologies, Inc. Apparatus and methods for the delivery of therapeutic liquids to the respiratory system
US6205999B1 (en) 1995-04-05 2001-03-27 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US6085740A (en) 1996-02-21 2000-07-11 Aerogen, Inc. Liquid dispensing apparatus and methods
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1997049805A2 (en) 1996-06-27 1997-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
EP1051493A2 (en) 1998-01-26 2000-11-15 Unilever Plc Method for producing antibody fragments
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
AP1447A (en) 1999-04-22 2005-08-12 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins.
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
EP1242460B1 (en) 1999-11-29 2006-10-18 Unilever Plc Immobilisation of proteins using a polypeptide segment
DK1233987T3 (da) 1999-11-29 2009-09-28 Bac Ip B V Immobiliserede enkelt-domæne antigenbindende molekyler
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003025020A1 (en) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Method of constructing camel antibody library
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
WO2005018629A1 (en) 2003-08-12 2005-03-03 Yarbrough William M Treatment for acne vulgaris and method of use
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
ES2379283T3 (es) 2005-05-18 2012-04-24 Ablynx N.V. Proteínas de unión a albúmina sérica
PL2444424T3 (pl) 2005-05-20 2019-01-31 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
TW200804593A (en) * 2006-01-24 2008-01-16 Domantis Ltd Fusion proteins that contain natural junctions
CA2644405A1 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
JP2010502208A (ja) 2006-09-08 2010-01-28 アブリンクス エン．ヴェー． 半減期の長い血清アルブミン結合タンパク質
WO2008049897A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
EP2557090A3 (en) 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US20100166734A1 (en) 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
CA2672944A1 (en) 2006-12-22 2008-07-03 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
PE20081610A1 (es) 2007-01-09 2008-12-09 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
RU2481355C2 (ru) 2007-05-24 2013-05-10 Аблинкс Н.В. Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей
EP2160409A1 (en) 2007-05-24 2010-03-10 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
WO2009068627A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
TW200938222A (en) 2007-12-13 2009-09-16 Glaxo Group Ltd Compositions for pulmonary delivery
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
CN102459332B (zh) 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
WO2011026945A1 (en) 2009-09-03 2011-03-10 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US9713589B2 (en) 2010-02-11 2017-07-25 Ablynx N.V. Methods and compositions for the preparation of aerosols

Also Published As

Publication number Publication date
WO2011098552A2 (en) 2011-08-18
PT3501499T (pt) 2022-11-22
EP2533761A2 (en) 2012-12-19
LT2533761T (lt) 2019-07-10
JP2018083839A (ja) 2018-05-31
CN102753148A (zh) 2012-10-24
CA2787718A1 (en) 2011-08-18
DK2533761T3 (da) 2019-06-24
HRP20191071T1 (hr) 2019-09-20
HUE044292T2 (hu) 2019-10-28
PL3501499T3 (pl) 2023-01-09
US20170333344A1 (en) 2017-11-23
WO2011098552A3 (en) 2012-03-29
CN105380904A (zh) 2016-03-09
JP5951508B2 (ja) 2016-07-13
CY1122634T1 (el) 2021-03-12
US20130019860A1 (en) 2013-01-24
EP3501499A1 (en) 2019-06-26
PT2533761T (pt) 2019-06-17
JP7019433B2 (ja) 2022-02-15
HK1222128A1 (zh) 2017-06-23
EP2533761B1 (en) 2019-03-27
US20210346287A1 (en) 2021-11-11
AU2011214299B2 (en) 2014-07-31
CA2787718C (en) 2018-05-15
SI2533761T1 (sl) 2019-08-30
JP2013519654A (ja) 2013-05-30
EP3501499B1 (en) 2022-09-07
US12083219B2 (en) 2024-09-10
US9713589B2 (en) 2017-07-25
US11007146B2 (en) 2021-05-18
JP6283064B2 (ja) 2018-02-21
ES2738114T3 (es) 2020-01-20
JP2016193923A (ja) 2016-11-17
AU2011214299A1 (en) 2012-08-02
CN102753148B (zh) 2018-01-26
ES2931330T3 (es) 2022-12-28

Similar Documents

Publication Publication Date Title
PL2533761T3 (pl) Sposoby i kompozycje do wytwarzania aerozoli
PL2841390T3 (pl) Stabilne wymiarowo kompozycje geopolimerów i metoda
BR112012015988A2 (pt) método
DK2640893T4 (da) Sammensætninger
LT2791160T (lt) Modifikuotos mrnr sudėtys
LT3246021T (lt) Apiksabano kompozicijos
BR112012031667A2 (pt) composição
BR112012017441A2 (pt) compostos e métodos
EP2554796A4 (en) TURBINE
PL2734049T3 (pl) Kompozycje probiotyczne i sposoby
SMT201600458B (it) Composizioni comprendenti buprenorfina
BR112014010450A2 (pt) composição e método
BR112012032683A2 (pt) composição
EP2540987A4 (en) TURBINE
DK3095817T3 (da) Mikrogelsammensætninger
EP2636704A4 (en) FILM FORMING COMPOSITION
EP2542347A4 (en) APPARATUS FOR PRECIPITATION OF PARTICLES
BR112012032980A2 (pt) composição
EP2628769A4 (en) FILM FORMING COMPOSITION
PL2635269T3 (pl) Kompozycja złożona
BR112013009024A2 (pt) método
BR112012023891A2 (pt) método
BR112012029669A2 (pt) composição e método
ZA201308892B (en) Compositions and methods
BR112014010860A2 (pt) composição e método